Biote Reports Q2 EPS 10c, Revenue $48.9M, Beats Estimate

Biote reported Q2 EPS of 10 cents, beating the consensus estimate of 13 cents. Revenue was $48.9M, slightly below the consensus of $49.5M. The company initiated an organizational restructuring to drive profitable growth and reported a 19.1% YoY increase in Adjusted EBITDA. Biote is focused on advancing its strategic priorities, including accelerating new providers, maximizing value from top-tier clinics, and strengthening its commercial organization.

Biote Corp. (BTMD) reported its second-quarter (Q2) 2025 earnings, with earnings per share (EPS) of 10 cents, surpassing the consensus estimate of 13 cents. Revenue for the quarter was $48.9 million, slightly below the consensus estimate of $49.5 million. The company also announced a significant organizational restructuring aimed at driving profitable growth [1].

The company's adjusted EBITDA increased by 19.1% year-over-year (YoY), reflecting a shift in the annual marketing event and efficiency gains from the vertical integration of its 503B manufacturing facility. Biote's gross profit margin improved to 71.6% from 68.8%, and net income turned positive at $3.9 million, compared to a net loss of $10.4 million in the prior year [2].

Biote's CEO, Bret Christensen, highlighted the progress made in reorganizing the commercial organization and aligning with strategic priorities, such as accelerating new providers, maximizing value from top-tier clinics, and strengthening the commercial organization. The company revised its fiscal 2025 revenue guidance to be greater than $190 million, up from the previously disclosed range of $202-$208 million, and Adjusted EBITDA guidance to be greater than $50 million, up from the previously disclosed range of $59-$64 million [2].

The stock has lost about 32.5% since the beginning of the year, compared to the S&P 500's gain of 7.1%. The company's earnings surprise of +66.67% this quarter and a history of beating consensus EPS estimates four times over the last four quarters suggest a positive trajectory for the stock [1].

References:
[1] https://www.nasdaq.com/articles/biote-corp-btmd-tops-q2-earnings-estimates
[2] https://finance.yahoo.com/news/biote-reports-second-quarter-2025-200500062.html